55 results about "Lipogenesis" patented technology

The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues.

The invention discloses a high-fiber sugarless bean dreg biscuit and a processing method thereof. The invention is characterized in that the bean dreg biscuit is prepared from the following raw materials in portions by weight: 100 portions of flour, 40-60 portions of dry bean dreg powder, 40 portions of corn starch, 25 portions of water, 16 portions of edible vegetable oil, 10 portions of egg, proper amount of swelling agent, proper amount of edible salt and proper amount of flavor. By fully utilizing the abundant proteins and celluloses and low fat content of the bean dregs, the invention can decelerate the absorption of the excess sugar by human bodies, eliminate the hunger sensation and inhibit the lipogenesis, thereby achieving the effect of losing weight.

A full-value feed for Estuarine puffer contains fish meal, starch, skin milk powder, spirulina, L-methionine, active glutelin, choline chloride, beer yeast and puffed soybean. It features rich nutrients.

The present invention relates to methods and compositions for modulating lipogenesis, lipid accumulation and lipid metabolism in a cell. These methods and compositions modulate genes which are controlled by LXRα, including the lipogenic transcription factor SREBP-1c.

The invention discloses herbal tea containing L-arabinose. The herbal tea comprises the following ingredients according to weight percent: 0.002%-10% of L-arabinose, 0.02%-3% of D-xylose, 0.2%-8% of stachyose, 0-15% of cane sugar and 64%-99.773% of pure water, and a proper quantity of food additives can be further added into the herbal tea. The herbal tea can regulate blood sugar level, reduce blood fat and relieve lipogenesis, solves the problem that the conventional herbal tea with high sugar and heat and low nutrition is not suitable for people wth diabetes, adiposis and the like, has a function of gut purging to solve the problems of constipation and toxin accumulation of people, can further dispel the effects of alcohol to protect the liver so as to solve the problem that the liver is damaged as people drink too much alcohol, and therefore, the herbal tea is healthy food for preventing diabetes, loosing weight, relaxing the bowels and protecting liver.

Biomarkers relating to de novo lipogenesis are provided, as well as methods for using such biomarkers in an Index to assess DNL. In addition, methods for diagnosing, determining predisposition to, and monitoring progression/regression of diseases related to DNL are provided. Also provided are methods of monitoring the efficacy of treatments for diseases related to DNL as well as other methods based on biomarkers of DNL.

Methods of culturing sebocyte cells, isolated populations of sebocytes, and methods of using the cultured sebocyte cells for screening compounds that inhibit or activate lipogenesis are provided.

The invention discloses a low fat chicken raising method, which comprises controlling growth velocity, and controlling lipogenesis through shortening feed time, wherein only plant fodder formulation is employed, and animal fat and feed stuff are strictly prohibited. By adopting different fodder formulation based on the physiological requirements of various growth phases of the chickens, the lipogenesis can be regulated and controlled.

A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPARγ, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-α1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs.

The invention discloses novel stilbene compound oligomers in sword iris (Iris lacteal Pall .var .chinensis(Fisch .)Koidz .) seed kernels as well as an extraction method and usage thereof. The extraction method of the novel stilbene compound oligomers in the sword iris seed kernels comprises the following steps: performing amplified preparation on an alkali extracted and acid precipitated product of sword iris seed kernels; and then, carrying out two times of preparation by adopting an aqueous cetonitrile solution as mobile phase so as to obtain the novel stilbene compound oligomers S11 in thesword iris seed kernels, namely VitisinA-13b-o-glucoside. The invention further provides application of the new compound S11 in preparation of medicines used for preventing and/or treating lipid metabolism disorder. And moreover, inhibition of cell lipogenic differentiation and lipogenesis by the novel stilbene compound oligomers S11 is verified by studying activity of the novel stilbene compoundoligomers S11; so that, the novel stilbene compound oligomers S11 can be used for preparing medicines which are capable of preventing or treating metabolic disorders, such as obesity, hyperlipidemia and the like.

The present invention provides a compound comprising a helminth-derived glycan and/or glycoconjugate thereof (e.g., a compound comprising a Lewis^x antigen (e.g., LNFPIII), a non-Lewis^x antigen (e.g., LNnT, LDN, and LDN derivatives), or a mixture of Lewis^x and non-Lewis^x antigens (e.g., SEA)), useful as a therapeutic compound for treating or preventing diseases associated with fat accumulation in the liver. The compounds of the invention are useful for treating or preventing the development of a fatty liver disease in a subject that has the disease or is at risk of developing the disease, and inhibiting lipogenesis in hepatocytes. The invention also provides methods of regulating the Erk-c-fos/AP-1-FXRα signalling pathway by administering a compound comprising a helminth-derived glycan and/or glycoconjugate thereof to a subject with a fatty liver disease, or contacting a hepatocyte with a compound comprising a helminth-derived glycan and/or glycoconjugate thereof.

AM580 and structurally related compounds have been found to be useful in treating infection by a wide range of RNA and DNA viruses, and also in reducing associated inflammation. This activity is independent of RAR-alpha signaling, and is not a result of activation of the hosts innate immune response. Broad antiviral activity of AM580 and structurally related compounds is a due to modulation of lipogenesis so as to correct disregulation of this pathway in virus-infected cells, via inhibition of nSREPBP.

The present invention relates to a pharmaceutical or food composition containing licochalcone A as an active ingredient for preventing, improving, or treating AMPK-related diseases, specifically, disorders involving lipid metabolism, hyperlipidemia, metabolic syndrome, obesity, fatty liver, or degenerative diseases (in particular, dementia). The pharmaceutical or food composition according to the present invention may significantly reduce adipocyte differentiation, adipocyte fat accumulation, and lipogenesis in hepatocytes, and may exhibit the effects of activating AMPK in hepatocytes. Accordingly, the pharmaceutical or food composition of the present invention can be effectively used for AMPK-related diseases, specifically, disorders involving lipid metabolism, hyperlipidemia, metabolic syndrome, obesity, fatty liver, or degenerative diseases (in particular, dementia).

In a composition and a microneedle for a localized obesity treatment containing the same in accordance with the present disclosure, the composition in accordance with the present disclosure contains a gelatin, decomposes a fat in a body, and inhibits lipogenesis and fat deposition in the body.

The present document describes apple peel polyphenolic extract comprising a proanthocyanidin content of at least 15000 μg/g of dry weight, comprising about 30% to about 35% epicatechin content, and pharmaceutical composition comprising the apple peel polyphenolic extract. The present document also describes methods and use of the apple peel polyphenolic extract for preventing or treating conditions such as oxidative stress, inflammation and mitochondrial dysfunction of the liver, insulin resistance, intestinal endothelial tissue injury, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), liver fibrosis, liver cirrhosis, and/or inhibition of de novo lipogenesis and β-oxidation of free fatty acids for preventing accumulation thereof in the liver. The present document also describes a process for extraction of at least a polyphenol content from dry apple peel powder.

The present invention discloses a fat eliminating and health preserving sweet orange drink which is prepared from the following raw materials by weight: 600-650 parts of sweet orange, 50-60 parts of strawberry, 20-25 parts of oats, 8-10 parts of apple enzyme powder, 15-20 parts of wine lees, 3-5 parts of winter collybia stipe dietary fibers and the like. The winter collybia stipe dietary fibers and psyllium shell powder contain soluble dietary fibers which can help human body to expel residues, and linden, chrysanthemum, garcinia pedunculata and the like are matched to achieve effects of slimming and swelling subsiding, and can inhibit lipogenesis to achieve the purpose of fat eliminating.

Provided in the present invention are adult stem cells derived from human skin dermis, and a method for isolating same. Further provided in the present invention are osteoblastic cells and adipocytes differentiated from the adult stem cells derived from human skin dermis, and a differentiation method therefor. Further provided in the present invention is a composition for osteogenesis or lipogenesis containing the stem cells, osteoblastic cells, or adipocytes. The isolation method of the present invention enables the adult stem cells derived from human skin dermis to be obtained in an easy and simple manner at a high yield rate. Genes and growth factors which are specifically expressed in the adult stem cells derived from human skin dermis isolated using the method can be separated, identified, and used later.